Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com

Mesoblast (NASDAQ:MESO) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $13.67.

Mesoblast Stock Down 0.7 %

MESO opened at $7.96 on Wednesday. Mesoblast has a 52-week low of $1.61 and a 52-week high of $10.24. The company has a 50 day moving average of $4.54 and a two-hundred day moving average of $2.99. The company has a market cap of $908.30 million, a P/E ratio of -7.10 and a beta of 3.45.

Institutional Investors Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MESO. Prosperity Wealth Management Inc. purchased a new position in Mesoblast in the 3rd quarter valued at about $79,000. Lazari Capital Management Inc. boosted its holdings in Mesoblast by 9.3% in the third quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock valued at $116,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Chase Investment Counsel Corp acquired a new stake in Mesoblast during the 1st quarter valued at approximately $298,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.